Protocol Ledger

NCT06747858 · Phase II · RECRUITING

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

Interventional Phase II clinical trial protocol NCT06747858 sponsored by Arcturus Therapeutics in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-12 Enrollment: 33 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06747858
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)33 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06747858
Protocol FieldVerified Registry Value
NCT IdentifierNCT06747858
Consolidated Lead SponsorArcturus Therapeutics
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment33 participants (ESTIMATED)
Registered Start Date2024-12-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06747858
Hospital Research SiteLocationSite Profile
University of ArizonaTucson, AZOpen Hospital Dossier ->
University of Arkansas for Medical SciencesLittle Rock, AROpen Hospital Dossier ->
Children's Hospital Los AngelesLos Angeles, CAOpen Hospital Dossier ->
Boston Children's HospitalBoston, MAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI